ZATELLI, Maria Chiara
 Distribuzione geografica
Continente #
NA - Nord America 21.937
AS - Asia 11.330
EU - Europa 6.984
SA - Sud America 1.978
AF - Africa 206
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 12
Totale 42.463
Nazione #
US - Stati Uniti d'America 21.462
SG - Singapore 4.872
CN - Cina 3.158
DE - Germania 1.867
BR - Brasile 1.665
IT - Italia 1.154
UA - Ucraina 1.141
HK - Hong Kong 1.124
VN - Vietnam 724
GB - Regno Unito 688
TR - Turchia 672
FI - Finlandia 494
RU - Federazione Russa 462
SE - Svezia 319
PL - Polonia 286
MX - Messico 217
CA - Canada 205
ID - Indonesia 176
IN - India 140
AR - Argentina 139
FR - Francia 133
ZA - Sudafrica 104
NL - Olanda 103
BD - Bangladesh 85
JP - Giappone 75
ES - Italia 69
AT - Austria 62
IQ - Iraq 61
BE - Belgio 52
PK - Pakistan 46
EC - Ecuador 45
LT - Lituania 44
VE - Venezuela 32
MA - Marocco 29
UZ - Uzbekistan 27
CO - Colombia 25
PY - Paraguay 19
UY - Uruguay 18
KE - Kenya 17
CL - Cile 15
IE - Irlanda 14
AE - Emirati Arabi Uniti 13
CZ - Repubblica Ceca 13
DO - Repubblica Dominicana 13
EG - Egitto 13
IL - Israele 13
NP - Nepal 13
SA - Arabia Saudita 13
AU - Australia 12
IR - Iran 12
PE - Perù 12
MY - Malesia 11
CH - Svizzera 10
EU - Europa 10
JO - Giordania 10
AL - Albania 9
DZ - Algeria 9
KR - Corea 9
PA - Panama 9
TN - Tunisia 9
JM - Giamaica 8
DK - Danimarca 7
LV - Lettonia 7
OM - Oman 7
PH - Filippine 7
RO - Romania 7
AZ - Azerbaigian 6
BG - Bulgaria 6
BO - Bolivia 6
PT - Portogallo 6
TT - Trinidad e Tobago 6
CR - Costa Rica 5
GA - Gabon 5
KG - Kirghizistan 5
KZ - Kazakistan 5
LB - Libano 5
SY - Repubblica araba siriana 5
AM - Armenia 4
BH - Bahrain 4
GR - Grecia 4
GT - Guatemala 4
HN - Honduras 4
KH - Cambogia 4
NG - Nigeria 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
TH - Thailandia 4
TW - Taiwan 4
BA - Bosnia-Erzegovina 3
HU - Ungheria 3
LA - Repubblica Popolare Democratica del Laos 3
LK - Sri Lanka 3
MK - Macedonia 3
PS - Palestinian Territory 3
SN - Senegal 3
BJ - Benin 2
BY - Bielorussia 2
ET - Etiopia 2
LU - Lussemburgo 2
MD - Moldavia 2
Totale 42.431
Città #
Singapore 2.799
Ashburn 2.597
Woodbridge 2.085
Fairfield 1.883
Chandler 1.487
Jacksonville 1.266
Houston 1.237
Santa Clara 1.124
Hong Kong 1.117
Beijing 1.047
Ann Arbor 842
Seattle 753
Wilmington 708
Cambridge 626
Izmir 410
Los Angeles 395
Nanjing 374
Dallas 370
Munich 363
New York 315
Princeton 313
Warsaw 283
Addison 276
Ho Chi Minh City 249
Ferrara 244
Milan 197
Boardman 185
San Diego 184
Shanghai 178
São Paulo 177
Hanoi 156
Mexico City 154
Jakarta 138
Turku 122
Helsinki 121
Shenyang 119
Nanchang 111
Dearborn 100
London 96
Bremen 92
Hefei 88
Hebei 85
Brooklyn 83
Chicago 83
Tianjin 81
Montreal 79
Denver 76
Buffalo 71
Moscow 70
Changsha 69
Tokyo 68
Orem 64
Washington 63
Johannesburg 61
Boston 60
Chennai 58
Atlanta 57
Mountain View 56
Phoenix 56
Stockholm 56
Toronto 56
Jiaxing 55
Falls Church 52
Jinan 52
Rome 52
Bologna 49
Frankfurt am Main 47
Rio de Janeiro 47
San Francisco 46
Nuremberg 45
Poplar 45
The Dalles 45
Brussels 44
Kunming 44
Falkenstein 43
San Jose 39
Redwood City 38
Belo Horizonte 37
Manchester 37
Guangzhou 36
Norwalk 36
Ankara 34
Council Bluffs 34
Da Nang 30
Amsterdam 29
Tappahannock 29
Baghdad 28
Campinas 28
Haiphong 28
Orange 26
Brasília 25
Hải Dương 25
Ningbo 25
Porto Alegre 25
San Mateo 23
Tashkent 23
Auburn Hills 22
Curitiba 22
Vienna 21
Biên Hòa 20
Totale 28.119
Nome #
SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma 398
Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds 285
Applicability of laparoscopic approach to the resection of large adrenal tumours: a retrospective cohort study on 200 patients 258
Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas 243
Proposal for a novel management of indeterminate thyroid nodules on the basis of cytopathological subclasses 235
Igf-I influences everolimus activity in medullary thyroid carcinoma 227
Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression 224
8th edition of the AJCC/TNM staging system of thyroid cancer: What to expect (ITCO#2) 224
A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization 222
Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism 219
Cyclin D1 levels are involved in the resistance to m-TOR inhibitors in human bronchial carcinoids 218
Role of Ultrasonographic/Clinical Profile, Cytology, and BRAF V600E Mutation Evaluation in Thyroid Nodule Screening for Malignancy: A Prospective Study 215
Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids 214
Magmas Overexpression Inhibits Staurosporine Induced Apoptosis in Rat Pituitary Adenoma Cell Lines 212
Proteasomes and RARS modulate AIMP1/EMAP II secretion in human cancer cell lines 209
Recettori della somatostatina e carcinoma midollare della tiroide: prospettive future. 208
Increase in Peripheral CD3-CD56brightCD16- Natural Killer Cells in Hashimoto's Thyroiditis Associated with HHV-6 Infection 207
Inhibition of epithelial growth factor receptor can play an important role in reducing cell growth and survival in adrenocortical tumors 203
Predictors of Pituitary Dysfunction in Patients Surviving Ischemic Stroke 202
Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. 199
Adrenal cavernous hemangioma: a case report 199
BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies 199
Relevance of BRAF(V600E) Mutation Testing Versus RAS Point Mutations and RET/PTC Rearrangements Evaluation in the Diagnosis of Thyroid Cancer 199
Are Evidence-Based Guidelines Reflected in Clinical Practice? An Analysis of Prospectively Collected Data of the Italian Thyroid Cancer Observatory 196
Early onset acromegaly associated with a novel deletion in CDKN1B 5'UTR region 194
Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells 192
Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion 190
Evaluation of the Role of BRAFV600E Somatic Mutation on Papillary Thyroid Cancer Disease Persistence: A Prospective Study 190
Functional characterization of a new deletion in CDKN1B 5'-UTR region 189
Virologic and immunologic evidence supporting an association between HHV-6 and Hashimoto’s thyroiditis 188
mTOR, AKT, p70S6K and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids 188
The cytotoxic effect of sunitinib on human bronchial carcinoid cell lines and primary cultures is counteracted by EGF and IGF-1 but not by VEGF 186
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression 185
Radio-guided selective compartment neck dissection improves staging in papillary thyroid carcinoma: a prospective study on 345 patients with a 3-year follow-up. 185
Involvement of PKCβ and PKCδ isoforms in TSH signaling pathway in thyroid cancer cell lines 183
Epidermal growth factor pathway as a possible target in the medical therapy of bronchial carcinoids 183
Allelic discrimination in the diagnosis of somatic BRAF V600E mutation on fine-needle aspiration biopsies 182
Magmas, a Novel Over-Expressed Gene in Pituitary Rat Cell Lines and in Human Pituitary Adenomas: A New Pituitary Biomarker? 180
IGF-I Proliferative Effects Are Inhibited by Targeting PKC in Human Endocrine Tumor Cells 179
Is there a correlation between BRAFV600 mutation, sentinel lymph node biopsy, pathological and clinical parameters in papillary thyroid carcinoma? 178
An in vivo OctreoScan-negative adrenal pheochromocytoma expresses somatostatin receptors and responds to somatostatin analogs treatment in vitro 177
BRAFV600E analysis on fine needle aspiration biopsy increases diagnostic accuracy for papillary thyroid cancer in clinically unsuspected nodules 177
Activation of the somatotropic axis by testosterone in adult men: evidence for a role of hypothalamic growth hormone (GH)- releasing hormone function 177
N-carbamidoyl-4-((3-ethyl-2,4,4-trimethylcyclohexyl)methyl)benzamide enhances staurosporine cytotoxic effects likely inhibiting the protective action of Magmas toward cell apoptosis 177
Acute administration of human galanin in normal subjects reduces the potentiating effect of pyridostigmine-induced cholinergic enhancement on release of norepinephrine and pancreatic polypeptide 175
X-linked acrogigantism syndrome: clinical profile and therapeutic responses 175
R171Q MEN1 polymorphism in patients presenting with hyperparathyroidism 175
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression. 174
Growth hormone excess promotes breast cancer chemoresistance 174
Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion 174
Acromegaly secondary to an incidentally discovered growth-hormone-releasing hormone secreting bronchial carcinoid tumour associated to a pituitary incidentaloma 173
VEGF autocrine secretion is enhanced by EGFR activation trough ERK1/2 phosphorylation in human adrenocortical carcinoma cell lines 172
Growth hormone induces chemoresistance in breast cancer cells 172
Cushing in a Leaf: Endocrine Disruption From a Natural Remedy 172
Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors 172
Antiproliferative effects of somatostatin analogs in pituitary adenomas 171
Presenza di HHV-6 in campioni tiroidei di pazienti con malattie autoimmuni della tiroide 171
MTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors 171
Should aip gene screening be recommended in family members of FIPA patients with R16H variant? 171
Evaluation of hormonal function in a series of incidentally discovered adrenal masses 170
Effects of two mTOR inhibitors on in-vitro models of GH-secreting pituitary adenomas 170
Magmas, a Gene Newly Identified as Overexpressed in Human and Mouse ACTH-Secreting Pituitary Adenomas, Protects Pituitary Cells from Apoptotic Stimuli 169
Therapeutic concentrations of mitotane (o,p′-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model 169
EGF and IGF1 affect sunitinib activity in BP-NEN: New putative targets beyond VEGFR? 169
mTOR, p70S6K, AKT and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids 168
RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease 168
Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells 167
Unexpected activation of pituitary-adrenal axis in healthy young and elderly subjects during somatostatin infusion 166
Differential mTOR and PI3K Pathway Activation in Human Bronchial Carcinoids 166
Magmas, a novel over-expressed gene in Pituitary rat cell lines and in human pituitary adenomas: a new pituitary bio marker? 165
Deletion of exons 1-3 of the MEN1 gene in a large Italian family causes the loss of menin expression 165
Neck paraganglioma and follicular lymphoma: A case report 165
miR-15a and miR-16-1 down-regulation in pituitary adenomas 164
HHV-6A in vitro infection of thyrocytes and T cells alters the expression of miRNA associated to autoimmune thyroiditis 163
mTOR mediated IGF1 proliferative effects on a rat pituitary GH/PRL secreting pituitary adenoma cell line 162
A new VHL polymorphism in a big family from Ferrara 161
Pituitary side effects of old and new drugs. 161
Growth Hormone Enhances Breast Cancer Chemoresistance by Inhibiting JNK-Mediated Apoptosis 160
Identification of differentially expressed microRNAs by microarray: A possible role for microRNA genes in pituitary adenomas 160
Recettori della Somatostatina e Carcinoma Midollare della Tiroide: prospettive future. 159
Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma 159
The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells 157
Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH) 157
In vitro testing of new somatostatin analogs on pituitary tumor cells 156
Evaluation of bone markers and structure in subclinical Cushing’s syndrome 156
Atypical femoral fractures as a complication of long-term bisphosphonate therapy 156
Efficacy of tolvaptan treatment in a patient with syndrome of inappropriate antidiuresis (SIAD) after severe traumatic brain injury 156
Utilization of luminescent technology to develop a kinase assay: Cdk4 as a model system 156
Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation 155
Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines 155
Prevalence and predictive factors of anterior hypopituitarism after ischemic stroke. 155
Cardiac and metabolic effects of chronic GH and IGF1 excess in young adults with pituitary gigantism 155
Efficacy and Safety of Teriparatide in Beta-Thalassemia Major Associated Osteoporosis: A Real-Life Experience 154
Cerebral aneurysm and acromegaly: a case report 153
Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet) 153
Levels of p27 sensitize to dual PI3K/mTOR inhibition 152
Bronchial carcinoid response to mTOR inhibitors depends on mTOR expression levels 152
An unusual association of hyperparathyroidism, ectopic GHRH secrection and bronchial carcinoid in a MEN1 family 152
Somatostatin receptor subtype 1 selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. 152
Effects of mTOR inhibitors in the control of non functioning pituitary adenomas cell growth 152
Totale 18.247
Categoria #
all - tutte 212.417
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 9.922
Totale 222.339


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.989 0 0 0 0 0 341 101 368 98 477 429 175
2021/20222.754 113 256 179 54 118 160 129 151 114 223 266 991
2022/20233.186 321 277 130 435 467 440 168 266 385 26 165 106
2023/20242.076 151 193 103 57 138 315 56 454 58 47 49 455
2024/20257.639 206 165 605 202 929 796 221 311 1.250 974 1.108 872
2025/202611.906 1.974 846 1.797 2.606 3.387 1.296 0 0 0 0 0 0
Totale 43.026